
Medpace Holdings (MEDP) Stock Forecast & Price Target
Medpace Holdings (MEDP) Analyst Ratings
Bulls say
Medpace Holdings is well-positioned for future growth due to strong pre-backlog growth, a diversified portfolio, and normalized cancellations. Furthermore, the company's shift toward oncology and tighter backlog recognition policy provide a structural buffer against potential future cancellation spikes. With a highly efficient headcount and an overall positive outlook for the biopharma industry, Medpace is in a strong position to continue its growth trajectory in the coming years.
Bears say
Medpace Holdings is a full-service contract research organization (CRO) focused on providing outsourced clinical development services to the biotech, pharmaceutical, and medical device industries. With a heavy reliance on the biotech industry, any slowdown in funding for these customers could severely impact Medpace's bookings and revenue growth. Additionally, any delays or cancellations of clinical trials could negatively impact the company's reputation and long-term performance, and there is also a risk of data breaches or a shortage of trained talent leading to slower clinical trial start times.
This aggregate rating is based on analysts' research of Medpace Holdings and is not a guaranteed prediction by Public.com or investment advice.
Medpace Holdings (MEDP) Analyst Forecast & Price Prediction
Start investing in Medpace Holdings (MEDP)
Order type
Buy in
Order amount
Est. shares
0 shares